Other Trials and Emerging Data in EGFR-Mutant NSCLC Treatment: Anticipating the Future Treatment Landscape

Opinion
Video

Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.

CN_FF_NSCLC_Seg07_Emerging
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What other trials/emerging data are you excited about in this treatment space? How do you anticipate the future treatment landscape to evolve for EGFR-mutant NSCLC?



      Recent Videos
      Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
      Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival
      A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
      Hospital Length of Stay After NSCLC Surgery Higher With Wildfire Exposure
      6 experts are featured in this series.
      Future Therapies for ALK+ Metastatic NSCLC
      6 experts are featured in this series.
      Evaluating ALK Inhibitors in Treatment Sequencing and Testing
      6 experts are featured in this series.
      Treatment Strategies in Disease Progression in ALK+ NSCLC
      6 experts are featured in this series.
      Patient Factors Considered when Choosing Treatment Selection
      6 experts are featured in this series.
      KRAS+ NSCLC: Treatment Management Strategies
      6 experts are featured in this series.
      Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?
      6 experts are featured in this series.
      KRAS G12 Inhibitor Treatment Options
      6 experts are featured in this series.
      Clinical Experience of Lorlatinib ALK+ NSCLC Patients
      Related Content
      Patients with ALK-positive NSCLC not vulnerable to neurological adverse effects or prone to weight issues, might benefit from treatment with lorlatinib.

      Considerations for TKI Selection and Sequencing in ALK-Positive NSCLC

      Roman Fabbricatore
      April 7th 2025
      Article

      Patients with ALK-positive NSCLC not vulnerable to neurological adverse effects or prone to weight issues, might benefit from treatment with lorlatinib.

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Improving NSCLC Surgery Recovery After Climate Disaster Exposure

      Leticia Nogueira, PhD, MPH
      March 31st 2025
      Podcast

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

      Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC

      Roman Fabbricatore
      March 30th 2025
      Article

      The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Navigating Management and Dosing Considerations for Amivantamab in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      February 10th 2025
      Podcast

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

      Prioritizing Climate Hazard Preparedness Following NSCLC Surgery

      Russ Conroy
      March 28th 2025
      Article

      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

      CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC

      CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC

      Tim Cortese
      March 27th 2025
      Article

      CAN-2409 plus valacyclovir or acyclovir elicited a median OS of 24.5 months in the overall population of patients who progressed after immune checkpoint inhibitor therapy.